Drugs / Indium-111-Octreoscan (standard test)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02078843 | Mar 2014 → Aug 2016 | digestive system neuroendocrine neoplasm | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indium-111-Octreoscan (standard test) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02078843 ↗ |
| Known as | Indium-111-DTPA-octreotide | “SRS using Indium-111-DTPA-octreotide (Indium-111-pentetreotide scintigraphy), is the most widely used diagnostic test.” NCT02078843 ↗ |